sotorasib,Midazolam
Amgen,Cipla
['ts,perio,i', 'codebreak 200', 'docetaxel', 'lumakras', 'ca,022,i', 'amgen']
 on august 30, 2022 amgen announced that the global phase 3 codebreak 200 clinical trial evaluating once-daily oral lumakras met its primary endpoint of progression-free survival, demonstrating superiority over standard-of-care chemotherapy, intravenous docetaxel.